The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | Phenotypes and molecular markers indicating elevated risk of RT in patients with CLL
Adam Kittai, MD, Ohio State University, Columbus, OH, discusses the phenotypes and molecular markers observed in patients which are associated with elevated risk of progression of chronic lymphocytic leukemia (CLL) into Richter’s transformation. Dr Kittai elaborates on the need for biopsy in patients exhibiting these symptoms. This interview took place at the 20th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy; Astrazeneca: Consultancy, Research Funding; Beigene: Consultancy; Janssen: Consultancy.
